Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T15:51:52.969Z.
Calculation as of: 2026-10-06T15:51:52.969Z.
Quote observation: 2026-10-06T15:49:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fc2e94c8beea8e322b310e9b25a1b89028fd55b2fc6a2790cf1d230843e32158
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$39.28M
EV/FCF Ratio
N/A
TTM Avg
20.47x
3Y Avg
71.52x
5Y Avg
76.62x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incannex Healthcare Limited (IXHL) | $38.35M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.28M | N/A | 20.47x | 71.52x | 76.62x |
| Edesa Biotech, Inc. (EDSA)vs › | $37.28M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.23M | N/A | N/A | N/A | N/A |
| Nephros, Inc. (NEPH)vs › | $40.06M | N/A | 32.59x | 41.40x | 41.40x |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $35.93M | N/A | 1.82x | 3.39x | 16.62x |
| QT Imaging Holdings, Inc. (QTI)vs › | $36.63M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.37M | N/A | N/A | N/A | N/A |
| BriaCell Therapeutics Corp. (BCTX)vs › | $35.58M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
